Duvadilan tab (Solvay)
Pregnin tab (Overseas)
Isoxsuprine is a prescription drug available from your pharmacy store only with the prescription of a qualified medical practitioner.
Isoxsuprine is pronounced as: eye SOCK soo prin
Isoxsuprine is a vasodilator.
Isoxsuprine is used in the management of condition where in there is poor blood flow in the arteries like Arteriosclerosis, Raynauds disease, cerebrovascular insufficiency and in the management & prevention of premature labor in pregnancy.
Do not use isoxsuprine in labor or just after the labor.
Pregnant woman: Isoxsuprine belongs to FDA pregnancy category C. This means that isoxsuprine may harm an unborn baby if used during pregnancy but potential benefit may warrant use of the drug in pregnant woman despite potential risks. Always inform your doctor if you are pregnant or are planning for conception.
Isoxsuprine is available in the form of tablet and injection.
Use as directed by your physician, your physician prescribes depending on the severity of disease. Use the complete course of medication as prescribed by your physician even though you feel better after one or two days of usage of medication.
If it is almost the time of the next dose, skip the missed dose and resume your usual dosing schedule. Do not take two doses at same time to cover up the missed dose.
In case of overdose contact your nearest poison control centre or emergency medical centre for immediate care by physician.
The overdose symptoms of Isoxsuprine are not known.
Isoxsuprine may cause following side effects
Consult your doctor immediately if the above symptoms worsen
Store isoxsuprine at room temp (15 – 30 degrees C). Avoid excessive heat, moisture or direct sunlight, never store in the bathroom.
Keep it out of reach of children. Make sure that any leftover portion is disposed off safely.
It is imp to read manufacturing packaging instruction carefully if available and always do not hesitate to consult pharmacist or physician for any information.
Written by: Healthplus24 team
Date last updated: May 31, 2012
Subscribe to our email newsletter.